Skip to main content
          Skip to FDA Search
          Skip to in this section menu
          Skip to footer links


U.S. flagAn official website of the United States government

					Here’s how you know
          			Dot gov**The .gov means it’s official.**Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
							      SSL**The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. 
			U.S. Food and Drug Administration
				
        Search
            Menu
							
						Search FDA
									
									Submit search 
		Featured
							Contact FDA
	                FDA Guidance Documents
	                Recalls, Market Withdrawals and Safety Alerts
	                Press Announcements
	                Warning Letters
	                Advisory Committees
	                En Español

					Products
            Food
							Drugs
							Medical Devices
							Radiation-Emitting Products
							Vaccines, Blood, and Biologics
							Animal and Veterinary
							Cosmetics
							Tobacco ProductsTopics
            About FDA
							Combination Products
							Regulatory Information
							Safety
							Emergency Preparedness
							International Programs
							News and Events
							Training and Continuing Education
							Inspections and Compliance
							Science and ResearchInformation For
            Consumers
	            Patients
	            Industry
	            Health Professionals
	            Federal, State and Local Officials 
 In this section:

                Report Problems to FDA

Report Problems to FDA Home
          Science & Research
          Science and Research Special Topics
          Clinical Trials and Human Subject Protection
          Report Problems to FDA
          Mandatory IRB Reporting: FDA ContactsReport Problems to FDA Mandatory IRB Reporting: FDA Contacts
  
  	
    Share
    Post
    Linkedin

    Email
    PrintUnder 21 CFR 56.113, an IRB shall have the authority to suspend or terminate approval of research that is not being conducted in accordance with the IRB's requirements or that has been associated with unexpected serious harm to subjects. Any suspension or termination of approval shall include a statement of the reasons for the IRB`s action and shall be reported promptly to the investigator, appropriate institutional officials, and the Food and Drug Administration.

21 CFR 56.108(b) requires that the IRB follow written procedures for ensuring prompt reporting to the IRB, appropriate institutional officials, and the Food and Drug Administration of:

Any unanticipated problems involving risks to human subjects or others;
	any instance of serious or continuing noncompliance with these regulations or the requirements or determinations of the IRB; or
	any suspension or termination of IRB approval.When reporting suspensions or terminations of IRB approval, please include the IND or IDE number, the full name of the research protocol, the name(s) of the clinical investigators, and the reason(s) for the suspension or termination. These reports may be submitted via e-mail or in hard copy by FAX or mail. Submit information to the following locations/contacts:

For Drug Products:

*Please report suspension or termination of IRB approval; unanticipated problems involving risks to human subjects; or serious or continuing noncompliance with the regulations or the requirements or determinations of the IRB to:*

Office of Scientific Investigations
Email: CDER-OSI-GCPReferrals@fda.hhs.gov
Phone: (301) 796-3150

For Biologic Products:

*Please report suspension or termination of IRB approval; unanticipated problems involving risks to human subjects; or serious or continuing noncompliance with the regulations or the requirements or determination of the IRB to:*

Email: CBERBIMONotification@fda.hhs.gov
Bioresearch Monitoring Branch
Division of Inspections and Surveillance
Office of Compliance and Biologics Quality
Center for Biologics Evaluation and Research/FDA
10903 New Hampshire Ave.
Building 71, Room 5126
Silver Spring, MD 20993
eFax: (301) 480-9748

For Medical Devices:

*Please report suspension or termination of IRB approval; unanticipated problems involving risks to human subjects; or serious or continuing noncompliance with the regulations or the requirements or determination of the IRB to:*

Phone (301) 796-5490
Fax: (301) 847-8136
Email: bimo@cdrh.fda.gov

                                                                                  Content current as of:
      03/07/2023Report Problems to FDA
 
 Footer Links
    FDA Archive
          About FDA
          Accessibility
      Visitor Information
          Website Policies / Privacy
          No FEAR Act
          Vulnerability Disclosure Policy
      FOIA
          HHS.gov
          USA.gov
    Contact FDA
      Follow FDA on Facebook
      Follow FDA on X
      Follow FDA on Instagram
      Follow FDA on LinkedIn
      View FDA videos on YouTube
      Subscribe to FDA RSS feeds
    FDA Homepage
    Contact Number
      1-888-INFO-FDA (1-888-463-6332) Back toTop